AbbVie's Rova-T Disappoints As Second-Line SCLC Trial Halted

 
• By John Davis
  
Golfer
The results of the TAHOE study are disappointing • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Anticancer

More from Therapeutic Category